​

Funding Round

Series C - Terns Pharmaceuticals

Series C - Terns Pharmaceuticals

Investment Firm

Overview

Terns Pharmaceuticals is a biopharmaceutical company that focuses on discovering therapies that will improve the global disease burden.

Announced Date

Jan 05, 2021

Funding Type

Series C

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

Deerfield

Deerfield

Deerfield is a debt and early_stage_venture firm.

Eli Lilly

Eli Lilly

No designation

Participant Investors

7

Investor Name
Participant InvestorOrbiMed
Participant InvestorEli Lilly
Participant InvestorDeerfield
Participant InvestorLilly Asia Ventures
Participant InvestorVivo Capital

Round Details and Background

Terns Pharmaceuticals raised $87000000 on 2021-01-05 in Series C

Terns Pharmaceuticals is a biopharmaceutical company that focuses on discovering therapies that will improve the global disease burden.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Oct 30, 2018
Series B - Terns Pharmaceuticals
4-80.0M
Jan 05, 2021
Series C - Terns Pharmaceuticals
7-87.0M
Aug 12, 2022
Post-IPO Equity - Terns Pharmaceuticals
2-65.0M
Dec 20, 2022
Post-IPO Equity - Terns Pharmaceuticals
-86.3M

Recent Activity

There is no recent news or activity for this profile.